


PE/Dazzle™ 594 anti-human IL-10

Catalog # /	3107130 / 100 tests
Size:	3107125 / 25 tests
Clone:	JES3-9D7
Isotype:	Rat IgG1, κ
Immunogen:	COS - expressed, recombinant human IL-10
Reactivity:	Human, Non-human primate, Other
Preparation:	The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Workshop Number:	V 5T CD27.03
Concentration:	Lot-specific




LPS-stimulated human peripheral blood mononuclear cells (in the presence of monensin) were surface stained with CD14 FITC, fixed, permeabilized, and then stained with IL-10 (clone JES3-9D7) PE/Dazzle™ 594 (top) or rat IgG1, κ PE/Dazzle™ 594 isotype control (bottom). Data shown was gated on monocyte population.

Applications:

Applications:	Intracellular Staining for Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells or 5 μ l per 100 μ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.



Application Notes: **Other Capture¹⁻⁵ or ELISPOT**
Capture⁶: The purified JES3-9D7 antibody is useful as the capture antibody in a sandwich Other, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502) as the detecting antibody and recombinant human IL-10 (Cat. No. 571009) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization^{1-3,9}: The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. No. 501407). The JES3-9D7 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Additional reported applications (for the relevant formats) include: immunohistochemical staining¹².
Note: For testing human IL-10 in serum or plasma, Other MAX™ Sets (Cat. No. 430601 to 430606) are specially developed and recommended.
 The JES3-9D7 antibody reacts with human and viral interleukin-10 (IL-10).

- Application References:**
1. Abrams J, et al. 1992. *Immunol. Rev.* 127:5. (Other Capture, Neut)
 2. Gotlieb W, et al. 1992. *Cytokine* 4:385. (Other Capture, Neut)
 3. Yssel H, et al. 1992. *J. Immunol.* 149:2378. (Other Capture, Neut)
 4. Abrams J. 1995. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.20. (Other Capture)
 5. Burdin N, et al. 1993. *J. Exp. Med.* 177:295. (Other Capture)
 6. Klinman D, et al. 1994. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.19. (ELISPOT Capture)
 7. Schaerli P, et al. 2000. *J. Exp. Med.* 192:1553.
 8. Jason J, et al. 1999. *Clin. Diagn. Lab Immunol.* 6:73.
 9. Akdis CA, et al. 1998. *J. Clin. Invest.* 102:98. (Neut)
 10. Stary G, et al. 2011. *J. Immunol.* 186:103. [PubMed](#)
 11. Mason GM, et al. 2012. *PNAS.* [PubMed](#)
 12. Smith DR, et al. 1994. *Am. J. Pathol.* 145:18. (IHC)

Description: IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRF1. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.

- Antigen References:**
1. Fitzgerald K, et al. Eds. 2001. *The Cytokine FactsBook*. Academic Press San Diego.
 2. de Waal-Malefyt R, et al. 1992. *Curr. Opin. Immunol.* 4:314.
 3. Howard M, et al. 1992. *Immunol. Today.* 13:198.
 4. Quesniaux V. 1992. *Research Immunol.* 143:385.